Core Insights - DoorDash is expected to report adjusted EPS of 58 cents per share on revenue of nearly $4 billion, despite being down nearly 30% in 2026 [1][2] - Analysts anticipate a core growth rate of over 20%, potentially exceeding 30% due to acquisitions [3][4] - Investors are focused on the company's investment cycle and its impact on margins, with expectations that margins can still rise despite ongoing investments [5][6] Company Performance - DoorDash has successfully diversified its operations beyond the U.S. through acquisitions in Eastern and Western Europe, as well as expanding into grocery and pharmacy delivery [8][9] - The company maintains a leading market share in the U.S. by effectively executing its strategy to onboard more merchants and improve delivery times [10][11] Investment Outlook - Evercore ISI has an outperform rating on DoorDash with a price target of $360, indicating significant upside potential [11][12] - The company is investing in AI and robotics for delivery, which could enhance productivity, although the timeline for fully autonomous delivery remains uncertain [14][15][16] Market Context - The stock has seen a downturn of nearly 40% from its all-time highs, with options markets pricing in a potential $20 move in either direction following earnings [19][20] - A bullish call diagonal strategy is being considered by traders, indicating a positive sentiment towards the stock's performance in the near term [21][24]

Core Insights - Walmart is expanding its delivery services to include chilled and reconstituted prescription medications, which is expected to sustain its 14% year-to-date stock performance [1] - This initiative positions Walmart as the first major national retailer to offer both cold-chain pharmaceutical delivery and basic grocery needs in a single order, impacting both local communities and the stock market [2] - The integration of high-value medications into Walmart's logistics aims to enhance customer loyalty through Walmart+ memberships and create competitive pressure on rivals like CVS and Amazon Pharmacy [3] Company Strategy - Walmart's pharmacy generates over 30% of its revenue from refrigerated prescriptions, and since launching its delivery service, it has completed over 4 million pharmacy deliveries [2][4] - The company has been preparing for this expansion for over a year, testing pharmacy delivery in 2024 and rolling it out to all locations by early 2025 [4] - The addition of cooled medications significantly broadens Walmart's market reach, as these products account for nearly one-third of pharmacy sales [5] Operational Capabilities - Walmart's cold-chain infrastructure includes insulated packaging and real-time monitoring, ensuring secure delivery of medications [6] - An electronic signature is required upon delivery, providing customers with assurance similar to that of a traditional pharmacy [6] Customer Engagement - The new delivery service is integrated into Walmart+, offering free delivery for members while non-members incur delivery fees, incentivizing more customers to join the loyalty program [7]